Korea Investment CORP Purchases 5,181 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Korea Investment CORP grew its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 9.2% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 61,457 shares of the biopharmaceutical company’s stock after purchasing an additional 5,181 shares during the period. Korea Investment CORP owned about 0.06% of Regeneron Pharmaceuticals worth $34,555,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Salomon & Ludwin LLC acquired a new stake in Regeneron Pharmaceuticals during the 3rd quarter worth $27,000. Migdal Insurance & Financial Holdings Ltd. acquired a new position in Regeneron Pharmaceuticals in the second quarter valued at about $31,000. Caitlin John LLC bought a new stake in shares of Regeneron Pharmaceuticals in the third quarter worth about $34,000. Traub Capital Management LLC bought a new stake in shares of Regeneron Pharmaceuticals in the second quarter worth about $38,000. Finally, Berbice Capital Management LLC raised its position in shares of Regeneron Pharmaceuticals by 300.0% during the second quarter. Berbice Capital Management LLC now owns 80 shares of the biopharmaceutical company’s stock worth $42,000 after purchasing an additional 60 shares during the period. 83.31% of the stock is owned by institutional investors.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, Director Bonnie L. Bassler sold 1,500 shares of the stock in a transaction dated Wednesday, January 7th. The shares were sold at an average price of $800.00, for a total transaction of $1,200,000.00. Following the completion of the transaction, the director directly owned 1,703 shares in the company, valued at $1,362,400. This represents a 46.83% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Jason Pitofsky sold 2,036 shares of the firm’s stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $778.52, for a total value of $1,585,066.72. Following the completion of the transaction, the senior vice president owned 4,272 shares of the company’s stock, valued at $3,325,837.44. The trade was a 32.28% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 5,274 shares of company stock worth $4,142,738 in the last three months. 7.02% of the stock is currently owned by company insiders.

Regeneron Pharmaceuticals Trading Up 2.9%

NASDAQ REGN opened at $781.60 on Tuesday. Regeneron Pharmaceuticals, Inc. has a 52 week low of $476.49 and a 52 week high of $821.11. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.39 and a current ratio of 4.13. The stock’s 50 day moving average price is $770.83 and its two-hundred day moving average price is $690.73. The stock has a market capitalization of $82.63 billion, a price-to-earnings ratio of 18.81, a PEG ratio of 2.04 and a beta of 0.40.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share for the quarter, topping the consensus estimate of $10.74 by $0.70. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. The company had revenue of $3.88 billion during the quarter, compared to analysts’ expectations of $3.76 billion. During the same period last year, the business earned $12.07 EPS. The business’s quarterly revenue was up 2.5% on a year-over-year basis. As a group, analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, March 5th. Investors of record on Friday, February 20th were given a $0.94 dividend. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. This is an increase from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. The ex-dividend date of this dividend was Friday, February 20th. Regeneron Pharmaceuticals’s payout ratio is 9.05%.

Analysts Set New Price Targets

Several brokerages recently issued reports on REGN. Wall Street Zen lowered Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Sunday. Guggenheim raised their target price on shares of Regeneron Pharmaceuticals from $865.00 to $975.00 and gave the stock a “buy” rating in a report on Monday, February 9th. BMO Capital Markets upped their price target on shares of Regeneron Pharmaceuticals from $725.00 to $850.00 and gave the company an “outperform” rating in a report on Thursday, December 4th. Barclays initiated coverage on shares of Regeneron Pharmaceuticals in a research report on Friday. They set an “overweight” rating and a $923.00 price objective for the company. Finally, HSBC started coverage on shares of Regeneron Pharmaceuticals in a report on Monday, November 24th. They set a “buy” rating and a $255.00 price objective on the stock. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have given a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $802.27.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.